Since APSP caused neurotoxicity [24] and istradefylline prevented the APSP following hypoxia/reperfusion, we therefore hypothesized that the FDA-approved A2AR antagonist may have neuroprotective potential in ex vivo and in vivo animal models of cerebral ischemia. Here, ADORA2A is linked to brain ischemia.